6 results  1 of 1 

1 Safety and Effectiveness Analysis of Kivexa® (lamivudine/abacavir sulfate) in Human Immunodeficiency Virus Infected Korean Patients
Heawon Ann, Yil-Seob Lee, Yeon-Sook Kim, Sook-In Jung, Sun-Hee Lee, Chang-Seop Lee, Jin-Soo Lee, Won Suk Choi, Young Hwa Choi, Shin-Woo Kim
Infect Chemother.2019;51(2):150-160.   Published online 2019 June 10     DOI: http://dx.doi.org/10.3947/ic.2019.51.2.150
      
2 Hypertension Risk with Abacavir Use among HIV-Infected Individuals: A Nationwide Cohort Study
Jungmee Kim, Ji Hwan Bang, Ju-Young Shin, Bo Ram Yang, Joongyub Lee, Byung-Joo Park
Yonsei Med J.2018;59(10):1245-1252.   Published online 2018 November 15     DOI: http://dx.doi.org/10.3349/ymj.2018.59.10.1245
      
3 Safety and Efficacy of Ziagen (Abacavir Sulfate) in HIV-Infected Korean Patients
Heawon Ann, Ki-Hyon Kim, Hyun-Young Choi, Hyun-Ha Chang, Sang Hoon Han, Kye-Hyung Kim, Jin-Soo Lee, Yeon-Sook Kim, Kyung-Hwa Park, Young Keun Kim, Jang Wook Sohn, Na-Ra Yun, Chang-Seop Lee, Young Wha Choi, Yil-Seob Lee, Shin-Woo Kim
Infect Chemother.2017;49(3):205-212.   Published online 2017 September 14     DOI: http://dx.doi.org/10.3947/ic.2017.49.3.205
      
4 Alopecia Areata Associated with Abacavir Therapy
Hee-Sung Kim, Hyoung-Shik Shin
Infect Chemother.2014;46(2):103-105.   Published online 2014 June 20     DOI: http://dx.doi.org/10.3947/ic.2014.46.2.103
      
5 Prevalence and Risk Factors of Low Bone Mineral Density in Korean HIV-Infected Patients: Impact of Abacavir and Zidovudine
Hee-Sung Kim, Bum Sik Chin, Hyoung-Shik Shin
J Korean Med Sci.2013;28(6):827-832.   Published online 2013 June 3     DOI: http://dx.doi.org/10.3346/jkms.2013.28.6.827
      
6 The First Case of Abacavir Hypersensitivity Associated with the HLA-B*57:01-Positive Allele in Korea
Ji Hyun Yoon, Mingoo Kim, Sung Joon Jin, Seung Kyu Kim, Seo Hui Lee, Jaeyoung Cheon, Gi young Yun, Min Kyung Kim, Jiyoon Ha, Young Goo Song
Infect Chemother.2012;44(5):399-402.   Published online 2012 October 31     DOI: http://dx.doi.org/10.3947/ic.2012.44.5.399
      

 1 of 1